Related Experiment Video
Updated: Oct 11, 2025

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
[Analysis of the treatment effect of posterior scleral reinforcement on pathological myopia]
1Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.
Abstract:
Pathological myopia, a blinding eye disease, is the most common cause of visual impairment in Asian countries. The most obvious features of pathological myopia are the elongation of the eye axis, the appearance of posterior scleral staphyloma, and even degenerative changes in the retina and choroid, resulting in corresponding complications and ultimately leading to marked visual impairment. Controlling the elongated eye axis is a key factor in preventing the complications of pathological myopia. Posterior scleral reinforcement is the main surgical method to delay the elongation of the eye axis and treat the posterior scleral staphyloma. Although most studies have confirmed that posterior scleral reinforcement is effective in delaying axial elongation and treating myopia, some scholars hold negative views on this surgery. This article summarizes the relevant research results of posterior scleral reinforcement surgery in the treatment of pathological myopia, concerning patients' vision, refractive power, eye axis, and corneal curvature, and discusses the effectiveness of the surgery. (Chin J Ophthalmol, 2021, 57: 952-957).
More Related Videos
12:25Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
Published on: January 6, 2018
05:46Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment